ON-013100 is primarily investigated for its potential in cancer therapy. It functions as a cell cycle inhibitor, specifically targeting and disrupting the proliferation of cancer cells. This compound has shown promise in preclinical studies for its ability to induce apoptosis in various cancer cell lines, making it a candidate for further development in oncology treatments. Researchers are exploring its efficacy in combination with other chemotherapeutic agents to enhance its anti-tumor effects. Additionally, its role in overcoming drug resistance in certain cancers is an area of active interest, potentially offering new avenues for treating challenging malignancies.